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Abstract In the 30 years since the original description of
ischaemic preconditioning, understanding of the patho-
physiology of ischaemia/reperfusion injury and concepts of
cardioprotection have been revolutionised. In the same
period of time, management of patients with coronary
artery disease has also been transformed: coronary artery
and valve surgery are now deemed routine with generally
excellent outcomes, and the management of acute coronary
syndromes has seen decade on decade reductions in car-
diovascular mortality. Nonetheless, despite these
improvements, cardiovascular disease and ischaemic heart
disease in particular, remain the leading cause of death and
a significant cause of long-term morbidity (with a con-
comitant increase in the incidence of heart failure) world-
wide. The need for effective cardioprotective strategies has
never been so pressing. However, despite unequivocal
evidence of the existence of ischaemia/reperfusion in ani-
mal models providing a robust rationale for study in man,
recent phase 3 clinical trials studying a variety of cardio-
protective strategies in cardiac surgery and acute ST-ele-
vation myocardial infarction have provided mixed results.
The investigators meeting at the Hatter Cardiovascular
Institute workshop describe the challenge of translating
strong pre-clinical data into effective clinical intervention
strategies in patients in whom effective medical therapy is
already altering the pathophysiology of ischaemia/reper-
fusion injury—and lay out a clearly defined framework for
future basic and clinical research to improve the chances of
successful translation of strong pre-clinical interventions in
man.
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Background
Since the original description of ischaemic conditioning
by Murry, Jennings and Reimer in 1986 [56], the
understanding of the mechanisms of cell death arising
from injurious ischaemia and reperfusion injury has been
transformed: no longer a purely necrotic model, it is now
recognised as a complex, multifaceted pathophysiological
process [37], involving not only necrosis, but also cellular
signalling, apoptosis, necroptosis [16] and the complex
interaction of autophagy [15] through to inflammatory
injury and pyroptosis [78] (Fig. 1). In parallel, identifi-
cation of numerous pharmacological targets, both in
modifying cell death pathways and in up-regulating
canonical conditioning signalling Reperfusion Injury
Salvage Kinase (RISK) [30] and Survivor Activating
Factor Enhancement (SAFE) [48] pathways that culmi-
nate in the inhibition of the mitochondrial transition pore
(mPTP, Fig. 2) have provided irrefutable proof of the
existence of reperfusion injury following injurious
ischaemia in animal models [32]. Moreover, the evolution
of remote ischaemic conditioning the phenomenon
whereby transient ischaemic stress of one organ can lead
to protection of another, remote organ such as the heart
against injurious ischaemia/reperfusion injury [33, 47] as
a putative therapeutic intervention that can be applied
prior to or immediately upon onset of reperfusion has
supported the existence of ischaemia/reperfusion injury in
man—both in proof-of-concept and meta-analysis of
phase 2 clinical trials [46].
Over the concomitant period of time, clinical epidemi-
ological data have clearly demonstrated what all practicing
cardiologists already knew: the rates of cardiovascular
mortality have been falling year-on-year over the last three
decades [55, 64]—through a combination of social changes
secondary to health education, improving primary and
secondary prevention and improved management of acute
coronary syndromes—not least through the introduction of
primary percutaneous intervention (PCI) and optimised
medical therapy. Nonetheless, while the efforts of cardio-
protective strategies such as primary PCI have led to
reduced early cardiovascular mortality, the ‘‘cardioprotec-
tion paradox’’ has been the incremental increase in the
number of patients living with the consequence of
myocardial injury: ischaemic cardiomyopathy and heart
failure [10, 55]. Ischaemic injury is the leading aetiology of
heart failure worldwide [55] and given that the propensity
to develop heart failure is related to the extent of the
primary myocardial injury [52], it is clear that further
intervention to reduce the initial myocardial injury is not
only desirable, but also necessary.
Ischaemic and pharmacological conditioning strategies
are promising interventions for further improving out-
comes, particularly for patients suffering from acute
myocardial ischaemia/reperfusion injury resulting from
ST-elevation myocardial infarction [69]. However, over
the last 12 months, a number of phase 3 clinical trials
studying cardioprotective modalities in a variety of clinical
settings have been published, the results of which have not
Fig. 1 Cartoon of injurious ischaemia/reperfusion injury and the
different forms of cell death. Necrosis is the prototypical form of cell
death resulting from prolonged ischaemia. Through high-energy
phosphate depletion, the cells cease to maintain electro-chemical
gradients and the cells and the intracellular organelles swell.
Histologically, the cytoplasmic membranes become progressively
more lucent, before rupturing leading to the dispersal of cellular
contents into the extracellular space (although the nuclei may persist).
The cellular contents, including both nucleic and mitochondrial DNA,
form damage associated molecular patterns (DAMPs); signals that are
also released into the extracellular space by necroptosis. Sharing
features with necrosis and programmed cell death, apoptosis,
necroptosis involves the recruitment of cellular pathways (typically
through receptor-interacting protein kinase (RIPK)), that may be
activated through the dissipation of DAMPS from neighbouring
necrosed cells. Like necrosis, but unlike apoptosis, the cell membrane
does not remain intact, and may lead to the release of further DAMPS.
The ensuing inflammatory reaction can then lead to pryoptosis—
inflammatory cytokine mediated injury. The consequence of the
spreading wave of dying cells, like toppling dominos, is likely
responsible for the formation of the characteristic confluent myocar-
dial infarct. Apoptosis, in contrast, is the ordered process of cell
death, through the successful completion of an ordered cellular shut-
down and compartmentalisation of potentially injurious cellular
contents that prevents unintended injury to neighbouring cells.
Autophagy plays a role in the house keeping of healthy cells,
removing senescent proteins and organelles, such as mitochondria
(mitophagy). During ischemia/reperfusion injury, autophagy may be a
double-edged sword: while autophagy may remove terminally injured
and dangerous organelles and oxidised proteins, contributing to
energy recovery in reperfusion, excess autophagy may be linked to
apoptosis and excessive substrate degradation
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been universally positive in demonstrating the anticipated
benefits in cardiovascular outcome.
Remote ischaemic conditioning in cardiac surgery
Two recent large clinical outcome studies investigating the
role of remote ischaemic preconditioning in cardiac sur-
gery have been contemporaneously published in the New
England Journal of Medicine. Remote Ischaemic Precon-
ditioning for Heart Surgery (RIPHeart) [54] and Effect of
Remote Ischaemic Preconditioning on Clinical Outcomes
in CABG Surgery (ERICCA) [27]. Both of these studies
sought to determine the efficacy of remote ischaemic
conditioning (four cycles of 5 min upper limb ischaemia
wrought by inflation of a blood pressure cuff to 200 mmHg
and 5 min reperfusion with cuff deflation) in patients
undergoing open-heart surgery and on-pump cardio-pul-
monary bypass. With broadly similar primary end-points of
death (any cause in RIPHeart, cardiovascular in ERICCA),
rates of non-fatal MI and cerebrovascular accident, neither
study was able to demonstrate a positive outcome for these
measures. Curiously, in contrast to earlier clinical CABG
trials, even differences in troponin release were not sig-
nificantly different between control and active treatment
groups. The reasons for the inability of these trials to
reproduce the clear efficacy of basic and earlier, smaller
clinical trials are unclear. One potential explanation may be
an interval improvement in surgical and anaesthetic man-
agement protocols that has led to improved cardiovascular
morbidity and mortality outcomes that has been observed
over the last three decades [60, 66]. Indeed, recent inno-
vations in surgical myocardial preservation techniques,
such as combined antegrade and retrograde myocardial
perfusion during bypass, are associated with smaller peri-
operative myocardial injury [12]. Thus speculatively,
optimisation of surgical and anaesthetic techniques may
have led to a progressively smaller peri-procedural
myocardial injury in patients undergoing CABG and valve
surgery in recent years. With smaller peri-procedural
injury, a type 1 statistical error is the likely consequence
for studies in which power calculations are based on his-
torical measures of myocardial injury and complications.
Reduction of peri-procedural injury represents a genuine
Fig. 2 Reperfusion Injury Salvage Kinase (RISK) and Survivor
Activating Factor Enhancement (SAFE) pathway model of ischaemic
conditioning. The acute ischaemic stress of non-injurious ischaemia
leads to the release of multiple stress-inducible factors that may
activate through G-protein coupled receptors (GCPR) or receptor
tyrosine kinases (RTK) to induce the RISK cascade, or through
inflammatory cytokines via the glycoprotein 130 (gp130) or tumour
necrosis factor receptor (TNFR) to activate the SAFE pathway. The
resulting signalling cascade then impacts upon mitochondria, poten-
tially inhibiting the mitochondrial permeability transition pore
(mPTP) and other mitochondrial proteins such as connexin-43
(Cx43), or via the nucleus to induce, through promotors, new protein
synthesis. PI3K (Phosphoinositide 3-kinase), Akt [Serine/threonine
kinase (protein kinase B)], eNOS (Endothelial nitric oxide synthase),
ERK (Extracellular signal-regulated kinases), JAK (Janus Kinase),
MEK (Mitogen-activated protein kinase kinase), NO (Nitric oxide),
p70S6K (p70 S6 ribosomal protein kinase), PKC (Protein Kinase C),
Ras/Raf (small GTPase proteins), STAT (Signal transducer and
activator of transcription)
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success for current surgical, anaesthetic and medical
management strategies for the benefit of patients, but it also
presents a diminishing target for additional benefit from
conditioning-type cardioprotective interventions.
The converse argument is that current anaesthetic
practice may be interfering with the cardioprotective
mechanisms triggered by interventions such as remote
ischaemic conditioning. Support for such a hypothesis can
be found in comparable troponin release profiles in studies
published over the last decade. Early, proof of concept
trials consistently demonstrate an approximate 30 %
reduction in the area under the troponin release profile
curve over 48–72 h—with Troponin-T (TnT) peaks at
6–12 h consistently in the range of 700 ng/L in control
patients. Interestingly, control patients in both RIPHeart
and ERICCA have comparable TnT release profiles to
these historical trials, but in contrast to the earlier studies,
remote ischaemic preconditioning had lost its efficacy in
reducing the release of this biomarker (ERICCA had a
10 % lower total troponin T release in patients who
received remote ischemic preconditioning, an effect that
was lost following multiple imputation analysis for missing
data points). It has been argued that anaesthetic agents such
as propofol may interfere with the canonical conditioning
pathway [44] and more than 90 % of patients in ERICCA
and all by protocol in RIPHeart, received propofol in
preference to volatile anaesthesia. While the role of
propofol is contentious (potentially cardioprotective in
some settings, but largely neutral in CABG [62]) and
biomarker release is not a clinical outcome, it may be
relevant that absence of attenuation of troponin release by
RIPC occurred in the two studies that did not demonstrate
an outcome benefit, implicating a loss of biological effect
[34]. Therefore, despite the neutral outcomes of RIPHeart
and ERICCA, important questions remain unanswered in
the context of cardiac surgery and the optimal anaesthetic
management in the pre-, peri- and post-operative phases.
Moreover, various peri-operative anaesthetic management
strategies, from propofol anaesthesia to the administration
of nitric oxide donors [e.g., intravenous glyceryl tri-nitrate
(GTN) [42]; currently prospectively investigated in the
ERIC-GTN trial [26]], require systematic careful investi-
gation. In the presence of a cocktail of anaesthetic agents
that may both inhibit canonical conditioning and are
themselves cardioprotective, it is perhaps unsurprising that
the demonstration of additional protection has become
extremely difficult and perhaps also unnecessary. More-
over, there are concerns regarding both the nature of peri-
procedural myocardial injury (i.e., how much is due to
ischaemia/reperfusion injury versus direct mechanical tis-
sue injury and perioperative inflammation) and the rele-
vance of the relatively small release of troponin seen
following cardiac surgery to clinical outcome has
consequently cast doubt on the relevance of modern car-
diac surgery as a model in which to test cardioprotective
strategies, although the impact of conditioning strategies
upon other post-surgical endpoints such as quality of life
[22] has yet to be fully evaluated. The group considered
that conditions that lead to greater myocardial injury (for
example, acute ST-elevation myocardial infarction) would
represent a better target for clinical study, with the poten-
tial for greater response to cardioprotective strategies in
which to demonstrate efficacy.
Therefore, while further investigations into the
myocardial benefit of remote ischaemic conditioning in
cardiac surgery are not a high priority, it was felt by the
group that close scrutiny and a more structured investiga-
tion into the optimal anaesthetic management of CABG
patients is certainly warranted.
Pharmacological cardioprotection in ST-elevation
myocardial infarction
Two phase 3 clinical studies investigating the efficacy of
two disparate pharmacological approaches in ST-elevation
myocardial infarction (STEMI) patients were discussed:
the Effect of METOprolol in cardioprotection During an
Acute Myocardial Infarction (METOCARD-CNIC) [38]
and Cyclosporine to ImpRove Clinical oUtcome in ST-
elevation myocardial infarction patients (CIRCUS) [20]
trials.
METOCARD-CNIC, a randomised, single-blinded, non-
placebo-controlled clinical trial investigating the efficacy
of metoprolol (a beta1-selective blocker) in attenuating
infarct size in patients undergoing primary PCI for STEMI,
was powered to demonstrate a 16 % reduction of infarct
size with metoprolol administration compared to control, as
measured by cardiac MRI. The study was positive,
demonstrating a 20 % reduction of infarct size and con-
comitant biologically plausible improvements in secondary
endpoints including ejection fraction and cardiac enzyme
release. METOCARD-CNIC has been followed by the
EARLY b-blocker administration before primary PCI in
patients with ST-elevation myocardial infarction (EARLY-
BAMI) study. Addressing the limitations of the earlier
METOCARD-CNIC study, this is a randomised placebo-
controlled, multi-centre, multinational trial but, at the time
of the meeting, the study had not reported. There are fur-
ther differences between the studies that may have an
impact upon outcomes: EARLY-BAMI is recruiting
patients with less restrictive inclusion criteria (infarcts of
any location and up to 12 h after pain onset, compared to
anterior STEMI only and 6 h in METOCARD-CNIC). The
timing and dose of metoprolol administration in the 2 trials
are also dissimilar: EARLY-BAMI has a 10 mg target dose
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of metoprolol (15 mg in METOCARD-CNIC), and the
second bolus of medication is given immediately before
reperfusion (in METOCARD-CNIC it was administered in
the out of hospital setting long before reperfusion). How-
ever, the early METOCARD-CNIC data is promising, and
while the mechanism of the protection following meto-
prolol administration is currently unknown, but may rep-
resent recruitment of a novel, non-canonical
cardioprotective pathway that reflect known beneficial
impacts upon inflammation [17] and arrhythmia [63, 75]
and deserves further study. If proven it offers an interesting
and useful inroad to modify ischaemia/reperfusion injury in
addition to existing conditioning-mimetic strategies.
Inhibition of the mitochondrial permeability transition
pore (mPTP) through pharmacological inhibition of
cyclophilin-D is one such conditioning-mimetic strategy.
The cyclophilin-D/mPTP is the putative end-effector of the
canonical conditioning cardioprotective pathway which
can be manipulated in the laboratory with cyclophilin
inhibitors such as Cyclosporine and sanglifehrin-A.
Cyclosporine-A appeared to be a promising candidate, with
positive proof-of-concept clinical trial data [61] following
a number of encouraging pre-clinical studies [29, 68]
demonstrating the efficacy of such an approach. However,
as has been widely reported elsewhere, the large clinical
outcome study, CIRCUS, was neutral. Published com-
mentaries have identified a number of potential explana-
tions for the disappointing result and the apparent
contradictory data when compared to earlier studies that
include the formulation of the Cyclosporine (in CIRCUS,
suspended in intralipid; intralipid itself having previously
been shown to be independently cardioprotective [31, 50]).
Other explanations were considered at the meeting to
explain the differences between the pre-clinical and early
proof-of-concept trials and CIRCUS, particularly in light of
further neutral data from the recent multi-centre, ran-
domised placebo-controlled, open-label CYCLE trial [59].
Experimental versus clinical endpoints
Experimental studies concentrate on the need to reduce
myocardial infarction, and predominantly concentrate on
short-term reperfusion (hours to 1–3 days maximum) fol-
lowing the injurious ischaemic insult. In contrast, the key
primary clinical outcome is patient survival following an
acute myocardial infarction—be that at 30 or 365 days. It
is not unreasonable to imagine that infarct size predicts
mortality, and to an extent it does [52]—but other variables
are at play, including ventricular remodelling and conse-
quent heart failure [36] that are not modelled in short-term
animal models. Extending pre-clinical animal studies to be
inclusive of longer reperfusion times may provide addi-
tional, clinically relevant information [72].
Type 1 error and overestimating benefit
Proof-of-concept trials perform a useful function, provid-
ing first-in-man evidence of a biological hypothesis, safety
data and a platform on which to plan future investigations.
What they are less capable of demonstrating is the genuine
size of any therapeutic benefit in a ‘‘real-world’’ clinical
setting—for which larger trials are necessary. Thus, posi-
tive proof-of-concept trials are interpreted with caution:
they risk type 1 statistical (false positive) errors, tend to be
undertaken in highly selected patient cohorts that make
wider interpretation problematical, and where positive may
over-estimate benefit of the study intervention. Conse-
quently, the resuls may prove impossible to replicate in
much larger, multi-centre/multi-national clinical trials with
broader admission criteria which may dilute the effect of
the cardioprotective intervention. Thus, while proof-of-
concept trials continue to play an important role in pro-
viding scientific validity to a research question, outcome
trials are necessary to demonstrate true clinical efficacy or
lack thereof in the real-world—and both approaches con-
tinue to have their place.
Is a single pharmacological targeted approach
appropriate?
CIRCUS attempted to target one facet of the complex
physiology of ischaemic conditioning: inhibition of
cyclophilin-D and by extension, inhibition of mPTP
opening. In fact, the mPTP is only partially inhibited even
in the complete absence of cyclophillin-D (reviews [9,
25]). However, it is becoming increasingly apparent that
cell death is not just mediated by a single channel in a
single organelle. Signs of cellular injury are found
throughout the injured cell: contractile apparatus, mito-
chondria, nucleus, sarcolemma, sarcoplasmic reticulum all
demonstrate the characteristic hall-marks of fatal ischae-
mia/reperfusion injury. Thus targeting a single pathway
may be naı¨ve: the optimum intervention may, in fact, be
the combination of multiple pathway targets in multiple
intracellular compartments/organelles in multiple cell types
that constitute the myocardium.
Pharmacology and pharmacokinetics
STEMI represents a particular challenge for drug interven-
tions designed to be cardioprotective. In order to imbue
resistance against injurious ischaemia and reperfusion, the
drug requires the necessary bioavailability at the appropriate
site (myocardium) at the appropriate time. For drugs that are
designed to be ‘‘anti-ischaemic’’—impacting on the ischae-
mic period of the pathophysiological process of acute
myocardial injury—any drug or remote conditioning signal
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needs to be able to permeate through into areas of the
myocardium where blood flow will, at best, be extremely
limited. Clinical trials investigating the potentially encour-
aging class of sodium/hydrogen exchange inhibitors (cari-
poride and eniporide in the GUARDIAN [70] and ESCAMI
[77] studies, respectively) failed to demonstrate a significant
reduction of myocardial necrosis in patients presenting with
STEMI. This has been attributed to both the lack of access
of these drugs to the ischaemic myocardium and the timing
of their administration which was, out of necessity, rela-
tively late into the injurious ischaemic insult, often just
minutes prior to the onset of reperfusion. Indeed, pre-clinical
data suggested that these drugs were only ever consistently
cardioprotective when administered prior to the onset of
injurious myocardial ischaemia, effectively negating their
utility in the context of STEMI [1].
A similar problem of drug access also affects reperfu-
sion-targeted therapy: while epicardial blood flow may
prove to be radiologically excellent following PCI, there is
no guarantee that microvascular flow will be preserved.
Indeed evidence of microvascular obstruction (MVO) can
be observed in approximately one-third of successfully
revascularized patients. Ischaemia/reperfusion-mediated
endothelial/microvascular injury and oedema may lead to
limited access for cytoprotective drugs, impacting upon
any potential beneficial effects one might hope to observe
[35]. Moreover, the milieu into which these therapies are
administered is made even more complex by interactions
with concomitantly administered drugs. An example of this
is the increasing recognition of the difficulties in obtaining
adequate P2Y12 platelet receptor inhibition following the
oral administration of direct, non-thienopyridine P2Y12
receptor inhibitors (e.g., ticagrelor) at the time of stent
placement in primary PCI. Alterations of gut blood flow
and attenuated absorption arise both as a direct conse-
quence of the activation of the sympathetic/parasympa-
thetic nervous systems following an acute myocardial
infarct and as a result of the co-administration of opiate
analgesics. Both significantly alter normal pharmacoki-
netics [45]. The optimal mode of administration of any
cardioprotective therapy would, therefore, appear to be
intravenous, but there are clear challenges in terms of
understanding how such a drug reaches the ischaemic
vulnerable zone in a timely and efficacious manner.
Hurdles to successful translation
There are a number of valuable lessons that can be taken
from the recent neutral cardioprotection trials that can be
applied to future basic science study and subsequent clin-
ical trial design to provide the best chance of successful
translation of a potentially effective therapy.
Animal models and reproducibility
In vitro, ex vivo and in vivo cell and animal studies remain
the backbone for basic research to determine the mecha-
nisms of cellular injury and to interrogate the cellular
cytoprotective pathways and determine likely successful
pharmacological targets that can be targeted to attenuate
cell death in the face of injurious ischaemia/reperfusion
injury. Data reproducibility is crucial. It is interesting to
note that there was controversy regarding the likely effi-
cacy of sodium-hydrogen exchange (NHE) inhibitors
administered after the onset of ischaemia prior to the
GUARDIAN and ESCAMI trials. Subsequently anxieties
were also voiced regarding the likely efficacy of adenosine
administration in this role prior to the largely neutral
AMISTAD trials [18]. Even with Cyclosporine-A, it is
unclear as to the drug’s efficacy in all species, with no
infarct sparing in rats treated with Cyclosporine-A at the
time of reperfusion in contrast to mice, and a meta-analysis
finding no evidence for an effect on myocardial infarct size
in swine [21, 51]. Therefore, it seems prudent to establish
scientific consensus with appropriately powered, blinded
and randomised pre-clinical animal trials prior to under-
taking translation into man, as has been recommended
previously [49, 65].
Optimal clinical outcome identification
Basic research studies often concentrate on short-term
reperfusion durations using infarct size as the primary end-
point. There is a clear need for these studies, and they have
a clear role in the development of hypotheses and delin-
eation of mechanisms of both cell death and cellular sal-
vage. However, in the pre-clinical translation pathway, it
would be helpful to demonstrate efficacy of particular
pharmaceutical interventions in animal models that perhaps
more closely reflect the clinical end-points that physicians
are striving to achieve in patients presenting with acute
coronary syndromes—particularly mortality and the mor-
bidity associated with loss of ventricular muscle, heart
failure.
It would therefore seem prudent to demonstrate efficacy
in reducing animal mortality and development of heart
failure in longer-term experimental studies, extending at
least until 30 days post-myocardial infarction.
Optimum clinical target identification
Cardiac surgery has in many ways been an ideal clinical
model of cardiac injury, with predictable onset of ischae-
mia and the restoration of flow following the completion of
a successful bypass procedure. However, the extent of
myocardial injury observed following cardiac surgery is
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significantly smaller than that seen following a presentation
with STEMI. Consequently, with a smaller injury, the
ability to detect a significant myocardial protective effect is
diminished. Combined with surgical and anaesthetic
improvements, it was felt by the group that it appears to be
time for the cardioprotection field to concentrate upon
areas of greatest clinical need with perhaps the greatest
chance of demonstrating clinical benefit, i.e., acute
myocardial infarction.
The duration of ischaemia: too much of a bad thing
As already indicated, the duration of myocardial ischae-
mia has an important influence not only upon the extent
of myocardial necrosis, but also upon the efficacy of a
cardioprotective intervention. Very short durations of
myocardial ischaemia may not result in a large enough
injury to observe a measurable improvement in terms of
myocardial salvage (and may even be exacerbated by
interventions such as ischaemic postconditioning [53]).
However very long durations of myocardial ischaemia not
only result in greater ischaemia/reperfusion injury, but
also have an impact upon the efficacy of the cardiopro-
tective strategy being employed. [11, 24] Modelling
clinically relevant ischaemia in small animals is difficult
and extrapolation of durations of ischaemia from small
animal models to humans is not direct. However, pre-
clinical data demonstrate a clear failure of interventions
such as ischaemic post-conditioning against more pro-
longed index ischaemia times [53] that needs to be
considered in context of clinical trial design. Interest-
ingly, the positive clinical outcomes in STEMI patients
are in those patients with comparatively short ischaemic
durations, being revascularised within 3–4 h from the
onset of symptoms [43]. It is notable that patients
recruited to the CIRCUS trial had a relatively long
ischaemic time; 18 % had an ischaemic time of greater
than 6 h.
The dose of the conditioning stimulus: too much
of a good thing
A comparatively under-studied potential pitfall of cardio-
protective clinical studies is the dose of the pharmacolog-
ical conditioning-mimetic or the number and duration of
ischaemic conditioning cycles used in patients. Almost all
cardioprotective drugs have dose–response curves with the
classical ‘‘U’’-shaped curve, which means more [drug]
does not mean more [protection]. This drug–response
characteristic is also evident with Cyclosporine-A, docu-
mented from its earliest characterisation [57]. Perhaps
surprisingly, the same ‘‘U’’-shaped dose–response rela-
tionship also exists with remote ischaemic conditioning:
increasing the duration of remote limb ischaemia may
ultimately lead to failure of the conditioning effect [41].
Unfortunately, the dose–response curves of many
pharmacological agents and of remote ischaemic condi-
tioning are not well characterised in man—and perhaps this
is largely due to the lack of a clear biomarker of cardio-
protection other than the attenuation of infarct size in
patients presenting with acute myocardial injury. However,
with remote ischaemic conditioning, the demonstration that
it is possible to take a blood sample and dialyse the car-
dioprotective moiety and infuse this in a Langendorff-
perfused rat heart [40, 67] may provide some useful
insights into the minimum and maximum number of con-
ditioning cycles required to imbue protection upon the
heart and the potential impact of a variety of co-morbidities
in patients who present with the sequelae of coronary artery
disease.
The influence of co-morbidities
Much has been written with respect to the adverse impact
of co-morbidities upon the efficacy of ischaemic condi-
tioning modalities [23]. In clinical practice, the critical co-
morbidity is coronary artery disease: the final common
pathophysiological pathway of the well-recognised car-
diovascular risk factors of diabetes, hypertension and
dyslipidaemia. In the sub-analysis of the CIRCUS study,
diabetes, hypertension and dyslipidaemia had no incre-
mental detrimental impact upon clinical outcome [20], and
therefore it would seem that establishment of coronary
artery disease itself is the critical process; the biological
milieu appears not to be further worsened by the contrib-
utory disease states.
How the milieu of multiple co-morbidities impacts upon
the efficacy of cardioprotective strategies is unclear. If the
clinical outcome data can be used as a guide, it appears that
multi-morbidity may be comparatively benign: the estab-
lishment of coronary artery disease may be the single co-
morbidity that increases the conditioning threshold, a
threshold that may not be further raised by the presence of
other cardiovascular risk factors (e.g., diabetes, hyperten-
sion and hyperlipidaemia). This is an interesting hypothesis
that requires further pre-clinical study.
Improving clinical care: the success hypothesis
The improving mortality figures associated with cardio-
vascular disease is a genuine success story [64] for which all
involved in the development and delivery of modern med-
ical interventions should be commended. Modern practice
has resulted in shorter ischaemic times wrought by the
introduction of reliable revascularisation through primary
PCI, but also reflects changes in medical management and
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pharmaceutical interventions. A typical patient presenting
with a STEMI will receive a cocktail of medications on the
way to, while in and following discharge from the coronary
catheter laboratory. At the time of initial diagnosis, loading
with aspirin and administration of opiate analgesics such as
morphine will be administered by paramedic teams during
transfer to the local heart attack centre. On arrival and
confirmation of STEMI by medical staff, loading of a P2Y12
inhibitor such as ticagrelor, will proceed as the patient is
transferred for the critical revascularisation procedure.
During the procedure, heparin, bivalirudin or GpIIbIIIa
inhibitors may be administered according to local prac-
tice—and on transfer to the coronary care unit, beta
blockers, statins and angiotensin converting enzyme inhi-
bitors will be initiated. While not all these therapies are
cardioprotective, opiates [8], P2Y12 inhibitors [74], GpII-
bIIIa inhibitors [3], beta blockers [39], statins [7] and ACE
inhibitors [4] have each been demonstrated to reduce infarct
size in basic science studies. Of these cardioprotective
drugs, only opiates, P2Y12 and GpIIbIIIa inhibitors are
reliably administered prior to the onset of reperfusion.
While aspirin is also administered in an appropriate time
window, there is no evidence to suggest that aspirin is
cardioprotective [74]. Therefore, opiates, P2Y12 and GpII-
bIIIa inhibitors, protective in the pre-clinical setting, have
the potential to inadvertently recruit canonical conditioning
pathways. Thus, through good medical practice, clinicians
may already be successfully conditioning their patients and
improving outcomes (see below and Fig. 3).
Future clinical trials need to be undertaken in the
environment of these agents, but pre-clinical studies should
also take cognisance of current clinical practice: as part of
the bench to bedside translation pathway, animal studies
ought be undertaken that reflect the current pharmacolog-
ical milieu of acute coronary syndrome patients, and be
shown to be effective on a background which includes
drugs such as morphine and P2Y12 inhibitors.
Novel cardioprotective strategies
P2Y12 inhibitors have already demonstrated significant
improvements in cardiovascular mortality [71, 76]. P2Y12
inhibitors have a strong anti-infarct effect in animal models
and the mechanism is dependent on the presence of pla-
telets in the blood [6, 19]. There is evidence that they may
protect by activating the canonical conditioning pathway:
P2Y12-induced protection depends on similar signalling
components as conditioning and adding ischemic post-
conditioning to the platelet inhibitor offered no additional
protection to a rabbit heart [74]. Moreover, ticagrelor also
inhibits adenosine re-uptake via the equilibrative nucle-
oside transporter, increasing adenosine and potentially
triggering conditioning via this route [13, 58]. P2Y12
receptors are not restricted to platelets, however, and may
also have impact upon inflammation (reviewed in [58]) that
may suggest non-canonical mechanisms of protection.
Given that myocardial injury is not restricted to the mito-
chondrion, other cardioprotective strategies that target a
non-RISK/SAFE pathway may offer additional benefits to
ischaemic or pharmacological conditioning. There are a
number of novel interventions that have either clinical
potential or have proven cardiovascular benefit. Matrix
metalloproteinase (MMP) inhibition [5, 14] and prevention
of mitochondrial DNA degradation [73] are examples of
the former, and sodium/glucose transporter (SGLT) inhi-
bition an example of the latter [79].
For MMP inhibition, pre-clinical data support a non-
canonical cardioprotective pathway that appears indepen-
dent of the RISK signalling pathway and cyclophilin-D
mitochondrial permeability transition pore regulation [5].
Moreover, early open-label clinical trial demonstrate pos-
itive cardiovascular outcomes following administration of
the MMP inhibitor, doxycycline [14]. MMP inhibition is
not alone in demonstrating a non-canonical protective
signature: inhibition of mitochondrial DNA degradation
and release using novel delivery of endonuclease-III also
represents a strong clinical target for the preservation of
myocardial viability [73]. Interestingly, it was felt that it
may be possible to apply a multi-modal approach to the
diminution of myocardial injury: building additive car-
dioprotection from disparate cardioprotective interventions
to maximise infarct limitation, which might be an attractive
route to further improving cardiovascular outcomes in the
current clinical paradigm.
SGLT inhibition has appeared virtually out of the blue as
a remarkable new intervention for the management of type-
2 diabetes. Developed as a therapeutic oral anti-hypergly-
caemic agent through targeting of renal SGLT2 transport
and promoting renal glucose clearance, the EMPA-REG
study [79] demonstrated for the first time that a treatment
for hyperglycaemia also has sizeable clinical benefits in
terms of reducing not only blood pressure, but also car-
diovascular mortality (without impacting on the frequency
of myocardial infarction of treated patients). The mecha-
nism by which this observation is mediated is unclear, but
with pre-clinical data supporting a link between SGLT and
reactive oxygen species generation [2], it is attractive to
postulate that these drugs may have direct cardioprotective
properties: a hypothesis that deserves further investigation.
The ten commandments of cardioprotection
Recent clinical trial results have been disappointing, failing
to deliver the anticipated patient benefit—but there is little
doubt of the validity of ischaemia/reperfusion injury as a
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target for intervention in patients presenting with acute
myocardial infarction. Further, large scale clinical trials—
CONDI-2 and ERIC-PPCI [28], two concurrent and allied
studies investigating remote ischaemic conditioning in
patients presenting with STEMI—are currently recruiting,
but recent data provides reason for reflection and consid-
eration as to how best develop a clinical translation path-
way so as to deliver clinical interventions with the best
chance of delivering a positive clinical outcome for
patients presenting with STEMI. The summary of the
workshop contributors can thus be distilled down to the
following ten points:
1. The cardioprotective intervention should be demon-
strated in multiple models, that should ideally
include large animals and models with co-morbidi-
ties, prior to clinical translation.
2. The data should be reproducible between laborato-
ries (we propose the formation of an international
laboratory consortium to ensure reproducibility of
randomised blinded animal studies).
3. End-points in late pre-clinical studies should reflect
the clinical endpoints that will influence clinical
practice (to include mortality).
4. Pre-clinical translational studies should start to
reflect the poly-pharmaceutical environments in
which cardioprotective strategies will be employed
in clinical trials—for example, on the background of
current medical therapy for STEMI patients (e.g.,
opiates, P2Y12 inhibitors etc.).
5. Although hypothesis demonstrating (proof of con-
cept) clinical studies have an important role in
studying the mechanisms of cardioprotection in man,
their outcomes require cautious interpretation in
regard to changes in clinical practice.
6. Large scale, all-comer trials are required to definitely
prove clinical benefit in patients presenting with
STEMI. These trials should have clearly defined
cardiovascular mortality and morbidity outcomes
and be powered appropriately.
7. Reperfusion injury should henceforth be referred to
as ischaemia/reperfusion injury to more accurately
reflect the true nature of the pathophysiology, and
the expected benefit of targeting both aspects.
8. Current management of CABG surgery is so good,
that it may be difficult to demonstrate further
cardioprotection. Therefore, CABG may not be a
robust enough model for examining ischaemia/
reperfusion injury: the success of current clinical
practice has resulted in an inadequate target for
cardioprotection.
Fig. 3 The conditioning stimulus and the impact of co-morbidity and
drug therapies. In animal and human studies, it is possible to trigger
cardioprotection with conditioning strategies—particularly if the
subjects are young and free from co-morbidity. However, the efficacy
of a conditioning stimulus is significantly blunted when there are co-
morbidities presence (age, diabetes, hypertension, hypercholestero-
laemia): the conditioning stimulus that was once effective, appears
suppressed, and unable to exceed a critical threshold required for
triggering protection. In contrast, with the ‘‘success hypothesis’’, we
find that medications already in regular use in patients presenting with
acute coronary syndromes are already cardioprotective in their own
right and likely already attenuating infarct size. Examples of these
include opiates, P2Y12 inhibitors, statins, beta blockers, etc. (see text).
Indeed, such a cocktail may be sufficient to trigger cardioprotection:
the drugs have already exceeded the conditioning threshold, will
reduce infarct size and optimise outcomes. While this makes the
demonstration of efficacy of ischaemic conditioning-type strategies
challenging, it represents a genuine benefit for patient outcomes.
Further optimisation may, however, require targeting alternate
mechanisms of cell injury
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9. Ischaemic conditioning is a powerful cardioprotec-
tive strategy in pre-clinical studies, but does not
represent the sole cardioprotective pathway in the
armamentarium against lethal ischaemia/reperfusion
injury. Therefore, future cardioprotective strategies
should aim to target multiple pathophysiological
pathways for optimal protective benefit.
10. Remote ischaemic conditioning is a safe, cost-
effective and non-invasive intervention that has been
proven to be effective in a number of pre-clinical and
clinical studies. A concerted effort is required to
ascertain the mechanisms by which this protection
occurs to maximise/optimise its potential benefits.
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